---
title: "Longshenrongfa Pharmaceutical Industry: The holding subsidiary has obtained the renewed \"Drug Production License\" and passed the drug GMP compliance inspection"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/252002283.md"
description: "Longshenrongfa Pharmaceutical Industry announced that its holding subsidiary, Gansu Puan Pharmaceutical Co., Ltd., has obtained the \"Drug Manufacturing License\" reissued by the Gansu Provincial Drug Administration, valid until March 2, 2026. This license covers the production of mixtures, membrane preparations, active pharmaceutical ingredients, etc., and the newly built production line for the annual output of 50 million boxes of cough syrup meets GMP requirements, which helps ensure market sales and product supply, actively promoting the company's future development"
datetime: "2025-08-07T10:00:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/252002283.md)
  - [en](https://longbridge.com/en/news/252002283.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/252002283.md)
generator: "portal-rs"
---

# Longshenrongfa Pharmaceutical Industry: The holding subsidiary has obtained the renewed "Drug Production License" and passed the drug GMP compliance inspection

Longshenrongfa Pharmaceutical Industry announced that its holding subsidiary, Gansu Puan Pharmaceutical Co., Ltd., recently obtained a "Drug Production License" approved by the Gansu Provincial Drug Administration and a "Drug GMP Compliance Inspection Notification." The renewed "Drug Production License" is valid until March 2, 2026, with the production address and scope located at No. 1, Nongda North Road, Huangyang Ecological Industrial Demonstration Park, Liangzhou District, Wuwei City, Gansu Province, including decoctions, film preparations, active pharmaceutical ingredients, pretreatment, and extraction, etc. The newly constructed production line for liquid preparations such as the annual output of 50 million boxes of cough syrup has been upgraded and transformed to meet the requirements of the "Drug Production Quality Management Standards" and is ready for production and operation, which is beneficial for further ensuring the market sales and product supply of cough syrup, and has positive significance for the company's future development

### Related Stocks

- [300534.CN](https://longbridge.com/en/quote/300534.CN.md)

## Related News & Research

- [Cell C publishes FY2026 annual report](https://longbridge.com/en/news/296585950.md)
- [Thales, Systematic partner to boost Danish air defense capabilities](https://longbridge.com/en/news/296363485.md)
- [CataCap buys majority stake in Danish data protection provider B4Restore](https://longbridge.com/en/news/296194758.md)
- [Rein Therapeutics releases corporate presentation on LTI-03 idiopathic pulmonary fibrosis program](https://longbridge.com/en/news/296389731.md)
- [Europe Gasoline/Naphtha-Gasoline refining margins rise](https://longbridge.com/en/news/296255145.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**